# INOMAGEN THERAPEUTICS, INC: A New and Disruptive Gene Based Therapy for Atrial Fibrillation

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | INOMAGEN THERAPEUTICS, INC |
| Location | CHICAGO, IL |
| Project | A New and Disruptive Gene Based Therapy for Atrial Fibrillation |
| Project number | 1R44HL187127-01 |
| Mechanism | R44 |
| Institute | National Heart Lung and Blood Institute |
| Award | $1,412,149 |
| Awarded | 2026-08-28 |
| Project period | 2026-09-01 to 2028-05-31 |
| UEI | G361MCGUDEE5 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11410004). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.